Skip to Content

Johnson & Johnson - Stock Quote JNJ

Rating as of

Morningstar's Johnson & Johnson Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Supported by a Solid and Diverse Portfolio, Johnson & Johnson Is Well-Positioned for Steady Growth

Karen Andersen, CFA Sector Strategist

Business Strategy and Outlook

| Damien Conover, CFA |

Johnson & Johnson stands alone as a leader across the major healthcare industries. The company maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that together create a wide economic moat.

Unlock Our Full Analysis With Morningstar Investor

Johnson & Johnson's Company Profile

Business Description

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.

One Johnson and Johnson Plaza
New Brunswick, NJ, 08933
T +1 732 524-0400
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Mar 31, 2022
Fiscal Year End Jan 2, 2023
Stock Type Classic Growth
Employees 144,300

Johnson & Johnson's Related News